A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

Trial Identifier: D798NC00001
Sponsor: AstraZeneca
Collaborator:
Arcus Biosciences, Inc
Start Date: July 2025
Primary Completion Date: February 2030
Study Completion Date: July 2032

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU East Melbourne, AU, 3002
AU Elizabeth Vale, AU, 5112
AU Nedlands, AU, 6009
AU North Adelaide, AU, 5000
AU Syndey, AU, 4032
CN Beijing, CN, 100142
CN Guangzhou, CN, 510060
CN Nanjing, CN, 2100008
CN Nanning, CN, 530021
CN Shanghai, CN, 200032
CN Xiamen, CN, 361003
GE Batumi, GE, 6010
GE Tbilisi, GE, 0186
GE Tbilisi, GE, 0114
GE Tbilisi, GE, 0112
KR Busan, KR, 48108
KR Seongnam-si, KR, 13620
KR Seongnam-si, KR, 13496
KR Seoul, KR, 03722
KR Seoul, KR, 06591
KR Seoul, KR, 5505
KR Seoul, KR, 03080
TW Kaohsiung, TW, 833401
TW Taichung, TW, 404327
TW Taichung, TW, 40705
TW Tainan, TW, 704
US, CA La Jolla, CA, US, 92037
US, CO Aurora, CO, US, 80045
US, MA Boston, MA, US, 02215
US, NY New York, NY, US, 10065
US, OH Cleveland, OH, US, 44106
US, TN Nashville, TN, US, 37232
US, TX Lubbock, TX, US, 79430